SG10201704472QA - Solid solution compositions and use in chronic inflammation - Google Patents

Solid solution compositions and use in chronic inflammation

Info

Publication number: SG10201704472QA
Authority: SG; Singapore
Prior art keywords: solid solution; chronic inflammation; solution compositions; compositions; inflammation
Prior art date: 2013-01-14

Richard Robert Reiley

Wilson Caparrós-Wanderley

Original Assignee

Infirst Healthcare Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-01-14Application filed by Infirst Healthcare LtdfiledCriticalInfirst Healthcare Ltd

2017-07-28Publication of SG10201704472QApublicationCriticalpatent/SG10201704472QA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Neurology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)

SG10201704472QA2013-01-142014-01-14Solid solution compositions and use in chronic inflammationSG10201704472QA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361752356P	2013-01-14	2013-01-14
US201361752309P	2013-02-04	2013-02-04

Publications (1)

Publication Number	Publication Date
SG10201704472QAtrue SG10201704472QA (en)	2017-07-28

Family

ID=50030251

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
SG11201505247TASG11201505247TA (en)	2013-01-14	2014-01-14	Solid solution compositions and use in cardiovascular disease
SG10201704472QASG10201704472QA (en)	2013-01-14	2014-01-14	Solid solution compositions and use in chronic inflammation
SG11201505241WASG11201505241WA (en)	2013-01-14	2014-01-14	Solid solution compositions and use in severe pain
SG11201505249VASG11201505249VA (en)	2013-01-14	2014-01-14	Solid solution compositions and use in chronic inflammation

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG11201505247TASG11201505247TA (en)	2013-01-14	2014-01-14	Solid solution compositions and use in cardiovascular disease

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
SG11201505241WASG11201505241WA (en)	2013-01-14	2014-01-14	Solid solution compositions and use in severe pain
SG11201505249VASG11201505249VA (en)	2013-01-14	2014-01-14	Solid solution compositions and use in chronic inflammation

Country Status (16)

Country	Link
EP (6)	EP2925367B1 (en)
JP (6)	JP6505607B2 (en)
KR (6)	KR20150125648A (en)
CN (4)	CN105007947B (en)
AU (4)	AU2014204734B2 (en)
BR (3)	BR112015015891B1 (en)
CA (3)	CA2898000A1 (en)
ES (4)	ES2875824T3 (en)
HK (3)	HK1216004A1 (en)
IL (5)	IL295091B2 (en)
MX (3)	MX379193B (en)
NZ (1)	NZ709486A (en)
RU (3)	RU2667977C2 (en)
SG (4)	SG11201505247TA (en)
WO (3)	WO2014108574A1 (en)
ZA (3)	ZA201505004B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9308213B2 (en)	2010-10-29	2016-04-12	Infirst Healthcare Limited	Solid solution compositions and use in chronic inflammation
US10695431B2 (en)	2010-10-29	2020-06-30	Infirst Healthcare Limited	Solid solution compositions and use in cardiovascular disease
US9744132B2 (en)	2010-10-29	2017-08-29	Infirst Healthcare Limited	Solid solution compositions and use in chronic inflammation
US11224659B2 (en)	2010-10-29	2022-01-18	Infirst Healthcare Limited	Solid solution compositions and use in severe pain
US9504664B2 (en)	2010-10-29	2016-11-29	Infirst Healthcare Limited	Compositions and methods for treating severe pain
US11730709B2 (en)	2010-10-29	2023-08-22	Infirst Healthcare Limited	Compositions and methods for treating severe pain
US11202831B2 (en)	2010-10-29	2021-12-21	Infirst Healthcare Limited	Solid solution compositions and use in cardiovascular disease
US10695432B2 (en)	2010-10-29	2020-06-30	Infirst Healthcare Limited	Solid solution compositions and use in severe pain
US8895536B2 (en)	2010-10-29	2014-11-25	Infirst Healthcare Ltd.	Compositions and methods for treating chronic inflammation and inflammatory diseases
US9271950B2 (en)	2010-10-29	2016-03-01	Infirst Healthcare Limited	Compositions for treating chronic inflammation and inflammatory diseases
WO2014108574A1 (en)*	2013-01-14	2014-07-17	Biocopea Limited	Solid solution compositions and use in severe pain
EP3988091A1 (en)*	2015-08-07	2022-04-27	InFirst Healthcare Limited	Solid solution compositions for nsaids
US10307388B2 (en)*	2016-12-29	2019-06-04	The United States Of America As Represented By The Secretary Of The Navy	Compositions and methods for diagnosis and treatment of inflammation
AU2018354090B2 (en)	2017-10-23	2024-10-24	Epitracker, Inc.	Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome
CA3099561A1 (en)*	2018-05-16	2019-11-21	Epitracker, Inc.	Compositions and methods for diagnosis and treatment of conditions related to aging
AU2019274431B2 (en)	2018-05-23	2025-03-13	Epitracker, Inc.	Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity
CN108653273A (en)*	2018-07-13	2018-10-16	昆明医科大学第附属医院	Artemisine compounds are as the application for preparing treatment Behchet's medicine
AU2019393256A1 (en)	2018-12-07	2021-07-29	Neurocrine Biosciences, Inc.	CRF1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
CN110251549B (en)*	2019-06-24	2021-12-03	浙江省肿瘤医院	Application of epimedium total flavone extract in preparing medicine for preventing and treating hashimoto thyroiditis
US20220249375A1 (en)*	2019-06-28	2022-08-11	Jiangsu Hengrui Medicine Co., Ltd.	Sustained-release lipid composition and preparation method therefor
NZ780733A (en)*	2019-07-21	2022-08-26	Scf Pharma Inc	Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof
WO2021158517A1 (en)*	2020-02-03	2021-08-12	Curemast, Inc.	Compositions and methods of use thereof for treatment of mastitis
RU2752764C1 (en)*	2020-12-14	2021-08-03	Общество с ограниченной ответственностью "Тривиум-ХХI" (ООО "Тривиум-ХХI")	Pharmaceutical composition with anti-inflammatory effect
IL306029A (en)	2021-03-27	2023-11-01	Trx Biosciences Ltd	Compositions having improved bioavailability of therapeutics
CN114601843A (en)*	2022-03-22	2022-06-10	重庆医科大学附属第一医院	Application of icariin in preparation of medicine for treating autoimmune uveitis
GB202208911D0 (en)*	2022-06-17	2022-08-10	Ravan Bio Limtied	Treatments

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3800038A (en)*	1972-04-21	1974-03-26	Biolog Concepts Inc	Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier
US5143934A (en)*	1990-11-21	1992-09-01	A/S Dumex (Dumex Ltd.)	Method and composition for controlled delivery of biologically active agents
GB9613858D0 (en)*	1996-07-02	1996-09-04	Cortecs Ltd	Hydrophobic preparations
CN1208047C (en)*	1997-07-29	2005-06-29	法玛西雅厄普约翰美国公司	Self-emulsifier for lipophilic compounds
US6063768A (en)	1997-09-04	2000-05-16	First; Eric R.	Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB2331458B (en)*	1997-11-21	2002-07-31	Gursharan Singh Moonga	Solubilising systems for difficult pharmaceutical actives for preparing concentrated stable solutions for encapsulation into soft gelatine
US7374779B2 (en)*	1999-02-26	2008-05-20	Lipocine, Inc.	Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248363B1 (en)*	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP2002544155A (en)*	1999-05-07	2002-12-24	ファルマソルゲーエムベーハー	Lipid particles based on a mixture of fluid and solid lipids and methods for producing them
KR20020011985A (en)*	1999-05-07	2002-02-09	파르마솔 게엠베하	Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
RU2246293C2 (en)*	1999-06-14	2005-02-20	Космо С.П.А.	Pharmaceutical compositions for oral administration with sustained-releasing active component and masking taste
IL148685A0 (en)*	1999-09-21	2002-09-12	Rtp Pharma Inc	Surface modified particulate compositions of biologically active substances
US6264981B1 (en)*	1999-10-27	2001-07-24	Anesta Corporation	Oral transmucosal drug dosage using solid solution
US20060034937A1 (en)*	1999-11-23	2006-02-16	Mahesh Patel	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
FR2805761B1 (en)*	2000-03-02	2002-08-30	Mainelab	LIPID NANOCAPSULES, METHOD OF PREPARATION AND USE AS A MEDICAMENT
US6455067B1 (en)*	2000-05-24	2002-09-24	Sang-A Pharmaceutical Co., Ltd.	Transdermal patch for nonsteroidal antiinflammatory drug(s)
JP2002284705A (en)*	2001-01-19	2002-10-03	Shiseido Co Ltd	Torpent
US20030105141A1 (en)*	2001-04-17	2003-06-05	Ping Gao	Finely self-emulsifiable pharmaceutical composition
AU2004258745A1 (en)*	2003-07-31	2005-02-03	Pharmacia & Upjohn Company Llc	Dispersible formulation of an anti-inflammatory agent
CA2540984C (en)*	2003-10-10	2011-02-08	Lifecycle Pharma A/S	A solid dosage form comprising a fibrate
AU2004291084A1 (en)*	2003-11-13	2005-06-02	Combinatorx, Incorporated	Methods and reagents for the treatment of inflammatory disorders
WO2005053689A2 (en)*	2003-12-01	2005-06-16	Lifecycle Pharma A/S	Pharmaceutical compositions comprising lercanidipine
WO2005079752A2 (en)*	2004-02-11	2005-09-01	Rubicon Research Private Limited	Controlled release pharmaceutical compositions with improved bioavailability
WO2005092370A1 (en)*	2004-03-22	2005-10-06	Solvay Pharmaceuticals Gmbh	Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
JP2008521807A (en)*	2004-11-24	2008-06-26	メルクエンドカムパニーインコーポレーテッド	Liquid and semisolid pharmaceutical formulations for oral administration of substituted amides
US20060138059A1 (en)	2004-12-28	2006-06-29	Vair Larry L Jr	Corona-treated polypropylene liquid filtration media
EP1874357A1 (en)*	2005-04-28	2008-01-09	Galenica Technology AB	Pharmaceutical dosage forms comprising a lipid phase
GB0610867D0 (en)*	2006-06-01	2006-07-12	Syntaxin Ltd	Treatment of pain
GB0704846D0 (en)*	2007-03-13	2007-04-18	Futura Medical Dev Ltd	Topical pharmaceutical formulation
RU2353349C2 (en)*	2007-04-18	2009-04-27	Общество с ограниченной ответственностью "Фармацевтические технологии"	Arthronosos cure
CN101129335B (en)*	2007-07-17	2010-09-22	浙江大学	Application of a nanostructure lipid carrier drug delivery system
WO2009153496A2 (en)	2008-05-26	2009-12-23	Genfit	Ppar agonist compounds, preparation and uses
GB201018289D0 (en)*	2010-10-29	2010-12-15	Biocopea Ltd	Treatment of respiratory disorders
AU2012213217B2 (en)*	2011-02-04	2017-04-20	Infirst Healthcare Limited	Compositions and methods for treating cardiovascular diseases
CN103442700B (en)*	2011-03-24	2016-04-06	利奥制药有限公司	Compositions containing lipidic nanoparticles and corticosteroid or vitamin D-derivatives
CN102793628B (en)*	2012-08-23	2014-07-02	东华大学	Liquid-solid mixed lipid nano-slow release system for cosmetic and preparation method thereof
WO2014108574A1 (en)*	2013-01-14	2014-07-17	Biocopea Limited	Solid solution compositions and use in severe pain

2014
- 2014-01-14WOPCT/EP2014/050638patent/WO2014108574A1/enactiveApplication Filing
- 2014-01-14EPEP14702460.8Apatent/EP2925367B1/enactiveActive
- 2014-01-14KRKR1020157021075Apatent/KR20150125648A/ennot_activeCeased
- 2014-01-14AUAU2014204734Apatent/AU2014204734B2/enactiveActive
- 2014-01-14CNCN201480006940.XApatent/CN105007947B/enactiveActive
- 2014-01-14SGSG11201505247TApatent/SG11201505247TA/enunknown
- 2014-01-14KRKR1020217009229Apatent/KR102338569B1/enactiveActive
- 2014-01-14SGSG10201704472QApatent/SG10201704472QA/enunknown
- 2014-01-14CNCN201480006216.7Apatent/CN104968368B/enactiveActive
- 2014-01-14RURU2015134142Apatent/RU2667977C2/enactiveIP Right Revival
- 2014-01-14MXMX2015009105Apatent/MX379193B/enunknown
- 2014-01-14WOPCT/EP2014/050637patent/WO2014108573A1/enactiveApplication Filing
- 2014-01-14SGSG11201505241WApatent/SG11201505241WA/enunknown
- 2014-01-14JPJP2015552094Apatent/JP6505607B2/enactiveActive
- 2014-01-14KRKR1020217040230Apatent/KR102491426B1/enactiveActive
- 2014-01-14KRKR1020157021073Apatent/KR102252574B1/enactiveActive
- 2014-01-14MXMX2015009106Apatent/MX377877B/enunknown
- 2014-01-14JPJP2015552096Apatent/JP6378694B2/enactiveActive
- 2014-01-14EPEP14703279.1Apatent/EP2943223B1/enactiveActive
- 2014-01-14ESES19188174Tpatent/ES2875824T3/enactiveActive
- 2014-01-14SGSG11201505249VApatent/SG11201505249VA/enunknown
- 2014-01-14KRKR1020237002149Apatent/KR20230017914A/ennot_activeCeased
- 2014-01-14ESES14702460Tpatent/ES2763352T3/enactiveActive
- 2014-01-14EPEP21164383.8Apatent/EP3858335A1/enactivePending
- 2014-01-14EPEP20192758.9Apatent/EP3795141A1/enactivePending
- 2014-01-14JPJP2015552095Apatent/JP6389190B2/enactiveActive
- 2014-01-14CNCN201480006298.5Apatent/CN104981253B/enactiveActive
- 2014-01-14BRBR112015015891-9Apatent/BR112015015891B1/enactiveIP Right Grant
- 2014-01-14BRBR112015015898-6Apatent/BR112015015898B1/enactiveIP Right Grant
- 2014-01-14AUAU2014204737Apatent/AU2014204737B2/enactiveActive
- 2014-01-14ILIL295091Apatent/IL295091B2/enunknown
- 2014-01-14ESES14703279Tpatent/ES2830033T3/enactiveActive
- 2014-01-14RURU2015134141Apatent/RU2675241C2/enactiveIP Right Revival
- 2014-01-14KRKR1020157021076Apatent/KR102235264B1/enactiveActive
- 2014-01-14CACA2898000Apatent/CA2898000A1/ennot_activeAbandoned
- 2014-01-14CACA2897884Apatent/CA2897884C/enactiveActive
- 2014-01-14EPEP19188174.7Apatent/EP3578172B1/enactiveActive
- 2014-01-14AUAU2014204735Apatent/AU2014204735B2/enactiveActive
- 2014-01-14ILIL282123Apatent/IL282123B/enunknown
- 2014-01-14CNCN201910070081.5Apatent/CN109549927B/enactiveActive
- 2014-01-14MXMX2015009104Apatent/MX377340B/enactiveIP Right Grant
- 2014-01-14CACA2897878Apatent/CA2897878A1/ennot_activeAbandoned
- 2014-01-14WOPCT/EP2014/050636patent/WO2014108572A1/enactiveApplication Filing
- 2014-01-14ESES14701930Tpatent/ES2829904T3/enactiveActive
- 2014-01-14EPEP14701930.1Apatent/EP2943222B1/enactiveActive
- 2014-01-14NZNZ709486Apatent/NZ709486A/enunknown
- 2014-01-14BRBR112015015858-7Apatent/BR112015015858B1/enactiveIP Right Grant
- 2014-01-14RURU2015134143Apatent/RU2674982C2/enactiveIP Right Revival
2015
- 2015-07-13ZAZA2015/05004Apatent/ZA201505004B/enunknown
- 2015-07-13ZAZA2015/05002Apatent/ZA201505002B/enunknown
- 2015-07-13ZAZA2015/05003Apatent/ZA201505003B/enunknown
- 2015-07-14ILIL239924Apatent/IL239924A0/enunknown
- 2015-07-14ILIL239923Apatent/IL239923A0/enunknown
- 2015-07-14ILIL239922Apatent/IL239922B/enactiveIP Right Grant
2016
- 2016-04-07HKHK16103939.0Apatent/HK1216004A1/enunknown
- 2016-05-18HKHK16105729.9Apatent/HK1217899A1/enunknown
- 2016-05-18HKHK16105732.4Apatent/HK1217651A1/enunknown
- 2016-11-11AUAU2016256804Apatent/AU2016256804B2/enactiveActive
2019
- 2019-03-27JPJP2019061720Apatent/JP2019116498A/enactivePending
2021
- 2021-08-27JPJP2021139210Apatent/JP7250865B2/enactiveActive
2023
- 2023-03-22JPJP2023045431Apatent/JP2023078365A/enactivePending

Also Published As

Publication number	Publication date
JP2016504403A (en)	2016-02-12
JP2016508155A (en)	2016-03-17
SG11201505241WA (en)	2015-08-28
IL282123A (en)	2021-05-31
EP2925367A1 (en)	2015-10-07
EP3795141A1 (en)	2021-03-24
HK1216004A1 (en)	2016-10-07
JP2016505625A (en)	2016-02-25
MX377340B (en)	2025-03-06
CA2897878A1 (en)	2014-07-17
JP6505607B2 (en)	2019-04-24
IL295091B1 (en)	2023-04-01
ZA201505002B (en)	2016-03-30
EP3578172A1 (en)	2019-12-11
EP2943223B1 (en)	2020-08-19
MX379193B (en)	2025-03-11
CN109549927B (en)	2022-03-29
AU2016256804A1 (en)	2016-12-01
KR102235264B1 (en)	2021-04-02
EP2943222A1 (en)	2015-11-18
AU2014204734A1 (en)	2015-07-23
ES2829904T3 (en)	2021-06-02
MX377877B (en)	2025-03-11
HK1217651A1 (en)	2017-01-20
ES2875824T3 (en)	2021-11-11
AU2014204734B2 (en)	2016-08-11
IL282123B (en)	2022-09-01
KR20230017914A (en)	2023-02-06
AU2014204737B2 (en)	2016-08-11
CA2898000A1 (en)	2014-07-17
CA2897884C (en)	2023-04-11
CN104968368A (en)	2015-10-07
ZA201505004B (en)	2016-03-30
EP3858335A1 (en)	2021-08-04
JP2021185179A (en)	2021-12-09
RU2674982C2 (en)	2018-12-14
AU2014204735B2 (en)	2016-08-11
RU2015134141A (en)	2017-02-16
KR102338569B1 (en)	2021-12-13
KR102491426B1 (en)	2023-01-26
SG11201505249VA (en)	2015-08-28
MX2015009104A (en)	2016-07-26
WO2014108572A1 (en)	2014-07-17
AU2016256804B2 (en)	2017-08-03
BR112015015898A2 (en)	2017-07-11
CN104981253A (en)	2015-10-14
ES2763352T3 (en)	2020-05-28
JP6389190B2 (en)	2018-09-12
WO2014108574A1 (en)	2014-07-17
ZA201505003B (en)	2016-03-30
RU2667977C2 (en)	2018-09-25
EP3578172B1 (en)	2021-03-24
BR112015015891A2 (en)	2020-10-27
EP2925367B1 (en)	2019-08-14
HK1217899A1 (en)	2017-01-27
MX2015009105A (en)	2016-06-21
BR112015015858A8 (en)	2018-01-16
CA2897884A1 (en)	2014-07-17
CN104981253B (en)	2019-05-10
AU2014204735A1 (en)	2015-07-23
KR20150125648A (en)	2015-11-09
CN109549927A (en)	2019-04-02
RU2018142676A (en)	2018-12-14
IL239922A0 (en)	2015-08-31
RU2015134142A (en)	2017-02-16
IL239923A0 (en)	2015-08-31
EP2943223A1 (en)	2015-11-18
CN105007947A (en)	2015-10-28
BR112015015891B1 (en)	2022-02-15
CN104968368B (en)	2018-05-04
RU2015134143A (en)	2017-02-21
IL295091B2 (en)	2023-08-01
NZ709486A (en)	2020-05-29
BR112015015858B1 (en)	2023-02-28
SG11201505247TA (en)	2015-08-28
IL295091A (en)	2022-09-01
BR112015015891A8 (en)	2017-07-11
BR112015015898A8 (en)	2018-01-23
WO2014108573A1 (en)	2014-07-17
KR20150125649A (en)	2015-11-09
AU2014204737A1 (en)	2015-07-23
IL239924A0 (en)	2015-08-31
BR112015015858A2 (en)	2017-07-11
JP2019116498A (en)	2019-07-18
KR102252574B1 (en)	2021-05-17
KR20210154261A (en)	2021-12-20
JP2023078365A (en)	2023-06-06
JP6378694B2 (en)	2018-08-22
BR112015015898B1 (en)	2022-04-12
RU2018142676A3 (en)	2022-01-17
RU2675241C2 (en)	2018-12-18
MX2015009106A (en)	2016-07-26
ES2830033T3 (en)	2021-06-02
KR20150125647A (en)	2015-11-09
CN105007947B (en)	2019-02-15
IL239922B (en)	2021-04-29
EP2943222B1 (en)	2020-08-26
JP7250865B2 (en)	2023-04-03
KR20210037742A (en)	2021-04-06

Publication	Publication Date	Title
HK1216004A1 (en)	2016-10-07	Solid solution compositions and use in chronic inflammation
HK1223975A1 (en)	2017-08-11	Nanobubble-containing composition and use thereof
GB201317286D0 (en)	2013-11-13	Composition and Use
GB201407698D0 (en)	2014-06-18	Improvements in and relating to ophthalmo-scopes
GB201321693D0 (en)	2014-01-22	Composition and uses thereof
PL2956471T3 (en)	2024-06-24	Il-1beta inhibitor composition and use thereof
PL3057441T3 (en)	2018-07-31	Composition preventing necrotic enteritis in galloanserae
IL276126B (en)	2022-05-01	Compositions comprising l-4-chlorokynurenine and uses thereof
EP3007720A4 (en)	2016-12-07	Compositions comprising gc- macrophage activating factor and uses thereof
HK1222561A1 (en)	2017-07-07	Compositions and methods for use in oncology
GB201301979D0 (en)	2013-03-20	New composition and use thereof
PL3068428T3 (en)	2023-03-13	Annexin ii variant compositions and methods
GB201318151D0 (en)	2013-11-27	Composition and device
GB2516064B (en)	2018-02-28	Improvements in and relating to radar
HK1222560A1 (en)	2017-07-07	Anti-influenza compositions and methods
GB201309050D0 (en)	2013-07-03	Improvements in and relating to cutlery
IL243091B (en)	2020-04-30	Compositions and methods for use in oncology
GB201322467D0 (en)	2014-02-05	Composition and use
GB201303143D0 (en)	2013-04-10	Improvements in and relating to radar
GB201304675D0 (en)	2013-05-01	Novel compositions having use in therapy
GB201311011D0 (en)	2013-08-07	Mavrik all in one
GB201301022D0 (en)	2013-03-06	Composition and uses thereof
GB201320958D0 (en)	2014-01-08	Improvements in and relating to medical devices
GB201301207D0 (en)	2013-03-06	Improvements in and relating to stabilisation systems

Movatterモバイル変換

SG10201704472QA - Solid solution compositions and use in chronic inflammation - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=50030251

Family Applications (4)

Family Applications Before (1)

Family Applications After (2)

Country Status (16)

Families Citing this family (26)

Family Cites Families (37)

Also Published As

Similar Documents